Artiva Biotherapeutics, Inc. (ARTV) stock
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.96−0.05 (-1.25%)
Close on Nov 16, 2026Market cap $193.61MP/E –Yield –
Artiva Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Artiva Biotherapeutics's operating margin for the twelve months ending Dec 31, 2024 was -26805.6%. For fiscal 2024 it was -26805.6%, against -91.6% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -26805.6% | −26714.0 |
| FY2023 | Dec 31, 2023 | -91.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | -5773.7% | – |
| Q4 FY2023 | Dec 31, 2023 | -509.4% | – |
| Q3 FY2023 | Sep 30, 2023 | 40.6% | – |
| Q2 FY2023 | Jun 30, 2023 | -338.1% | – |
See a number that looks wrong?